CFCM Daily Radar — Myeloma Antigen Heterogeneity, AML Resistance and BCMA Immunity
Ramantamig and BCMA/GPRC5D heterogeneity lead the 11 October radar, alongside pediatric AML mitochondrial transfer, GPR56-linked venetoclax resistance and anti-BCMA immune effects.
Published 11 October 2026. CFCM editorial selection; peer-reviewed evidence and translational limitations are labelled explicitly.
Paper of the Day — Dual targeting of BCMA and GPRC5D in myeloma
Peer-reviewed original research
Chloe O'Neill, Marloes E. C. Broekmans, Charlotte L. B. M. Korst and colleagues. Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma. HemaSphere. Published 7 October 2026. DOI: 10.1002/hem3.70487.
In bone marrow samples from 42 patients, the study identified BCMA⁺/GPRC5D⁺, single-positive and double-negative myeloma populations. Mean proportions were 61%, 15%, 12% and 12%, respectively. In ex vivo testing, the dual-target trispecific antibody produced greater tumour-cell lysis than single-target controls. These are experimental cytotoxicity data, not clinical response rates.
Why it matters to CFCM: therapeutic-target phenotyping should report both the fraction of positive cells and expression intensity. Binary positive/negative summaries can hide clinically relevant heterogeneity and potential escape populations.
Daily Learning Pill — Two targets are better than one, but double-negative cells still matter
A dual-target therapy can broaden coverage across heterogeneous tumour populations, but flow-cytometric negativity depends on antigen density, antibody binding, background and assay sensitivity. “Negative” does not necessarily mean complete biological absence.
Academy reuse: Multiple Myeloma → Panel Design → Therapeutic Target Phenotyping and Detection Limits.
AML biology — Mitochondrial transfer can reprogram macrophages
Peer-reviewed original research
Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML. Leukemia. Published 9 October 2026. DOI: 10.1038/s41375-026-03164-1.
The study links mitochondrial transfer from AML cells to macrophages with altered metabolic state, changes in CD80, HLA-DR, CD163 and CD206, impaired phagocytosis and reduced T-cell-mediated tumour killing in experimental systems.
CFCM placement: News → Haematological Malignancies; Academy → Functional Cytometry.
Technology Radar — GPR56 and venetoclax resistance
Peer-reviewed mechanistic research
Increased mitochondrial biogenesis by GPR56 contributes to venetoclax resistance in acute myeloid leukemia. Cell Death & Disease. Published 9 October 2026. DOI: 10.1038/s41419-026-09225-8.
The work links higher GPR56 expression to venetoclax resistance through mitochondrial biogenesis and associated signalling. It does not establish a validated clinical flow-cytometric threshold for treatment selection.
CFCM placement: Intelligence → Technology Radar; Academy → AML Biology.
Immunomonitoring — Anti-BCMA therapy and antiviral immunity
Peer-reviewed scientific letter with original analyses
Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma. HemaSphere. DOI: 10.1002/hem3.70455.
High-dimensional spectral cytometry identified rapid depletion of plasmacytoid dendritic cells after anti-BCMA treatment, with reduced IFN-α responses after TLR9 stimulation. The study supports a mechanistic immune effect but does not validate pDC counts as an individual infection-risk predictor.
CFCM placement: Academy → Immunomonitoring; Intelligence → Technology Radar.
Editorial decision
The ramantamig study is the featured scientific item. The AML macrophage paper is the strongest separate News story. GPR56 belongs in Technology Radar, while the anti-BCMA pDC findings provide important supporting context for treatment-associated immune monitoring.
Evidence note
Scientific claims above refer to identifiable peer-reviewed publications. Ex vivo cytotoxicity is not presented as patient response, and biomarker discovery is not presented as clinical assay validation.
About the author
Juan Manuel Ojeda — Founder & Editor, CFCMProfessional background includes Sysmex, Newcastle University and the NHS. CFCM is Juan Manuel Ojeda's independent editorial project and represents the author alone. Manufacturer references do not imply endorsement. Relevant professional or financial relationships are disclosed alongside the affected coverage.
Related: validation and analysis resources →Clinical Notes →Published 11 October 2026. CFCM source checking and editorial qualification are not independent scientific review.